IL1B and atherosclerosis: Furthermore, the CANTOS trial confirmed the inflammatory hypothesis of atherosclerosis as well as the significant role of IL-1β in the pathogenesis of atherosclerosis, although this did not result in approval of the studied IL-1β-inhibitor canakinumab due to higher rates of infection in the active treatment group [8].